ECILC:BISTEIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. Analysis
Data as of 2026-03-17 - not real-time
TRY 116.40
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ECILC trades well above its 20‑day (≈116) and 50‑day (≈114) SMAs, confirming a bullish price bias, yet the MACD shows a bearish histogram and the signal line sits above the MACD line, hinting at short‑term momentum weakness. The RSI hovers around the neutral 50 mark, and the stock sits comfortably above the identified support at ~105 but still faces a strong resistance near ~131. Fundamentally, the company carries a high PE of ~38 versus an industry average of ~26 and a DCF fair value of only ~15, flagging a severe overvaluation, while revenue is contracting (‑2.5%) and leverage is elevated (debt‑to‑equity >5). Nonetheless, a 1.5% dividend yield backed by a 57% payout ratio and ample cash reserves provides some income cushion.
Bottom line: bullish technical positioning is offset by lofty valuation, modest growth, and leverage concerns, suggesting caution despite the dividend appeal.
Bottom line: bullish technical positioning is offset by lofty valuation, modest growth, and leverage concerns, suggesting caution despite the dividend appeal.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above short‑term SMAs supports bullish bias
- Bearish MACD histogram signals possible near‑term pullback
- Extreme overvaluation relative to DCF and peers
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained dividend yield offsets valuation concerns
- Revenue contraction and high leverage limit upside
- Sector stability but regulatory environment remains uncertain
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Valuation gap (market price vs. DCF) is unlikely to close without fundamental catalyst
- Weak growth outlook and elevated debt‑to‑equity increase financial risk
- Potential regulatory and macro‑economic headwinds in Turkey
Key Metrics & Analysis
Financial Health
Revenue Growth-2.50%
Profit Margin21.16%
P/E Ratio38.2
ROE3.94%
ROA0.68%
Debt/Equity5.18
P/B Ratio1.4
Op. Cash FlowTRY1.4B
Free Cash FlowTRY632.8M
Industry P/E26.4
Technical Analysis
TrendBullish
RSI51.2
SupportTRY 105.40
ResistanceTRY 131.40
MA 20TRY 116.11
MA 50TRY 114.33
MA 200TRY 81.42
MACDBearish
VolumeDecreasing
Fear & Greed Index78.09
Valuation
Fair ValueTRY 14.98
GradeOvervalued
TypeValue
Dividend Yield1.53%
Risk Assessment
Beta0.08
Volatility56.99%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.